StrideBio Secures Seed Funding to Advance its Novel AAV Platform

Hatteras Venture Partners has provided seed capital

Durham, N.C., May 30, 2017 – StrideBio, Inc, a US-based company developing novel AAV vectors for in vivo gene delivery applications announced today that it had raised a seed round of capital from Hatteras Venture Partners to help support the ongoing growth of the company.

StrideBio’s AAV vector development platform makes use of structure-guided evolution to discover novel capsids with improved properties for in vivo gene delivery applications. The underlying technology is based on the work of Dr. Aravind Asokan at the University of North Carolina at Chapel Hill and Dr. Mavis Agbandje-McKenna at the University of Florida.

“We are excited to have Hatteras as a partner, as we continue to build out our AAV platform and advance our early stage programs. Our deep understanding of how neutralizing antibodies interact with different AAV serotypes has led us to identify a number of novel capsids that we are moving forward in development. We are also pleased to announce this early funding on the heels of our collaboration with CRISPR Therapeutics and Casebia,” said Mavis Agbandje-McKenna, co-founder of StrideBio, Inc.

“StrideBio is the latest company we have seeded through our Hatteras Discovery effort and we look forward to working with the team to support the company’s continued growth,” said Clay Thorp, General Partner, Hatteras Venture Partners. “Gene therapy remains an exciting area for investment and we believe the company’s novel platform will generate unique AAV capsids for both its own pipeline and for its partners.”

About StrideBio

StrideBio, Inc is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) vector technologies and therapeutics for rare diseases. Our STRucture Inspired DEsign approach holds the potential to generate unique AAV capsids capable of overcoming the challenges of pre-existing neutralizing antibodies and improving gene transfer efficiency in patients. This powerful new approach has broad application, enabling gene addition, gene silencing and gene editing modalities for a wide range of diseases, including rare genetic diseases. StrideBio is headquartered in Durham, NC. For more information, please visit

About Hatteras Venture Partners

Hatteras Venture Partners is a venture capital firm based in Durham, NC with a focus on seed and early stage healthcare investing. The firm focuses on biopharmaceutical, healthcare IT, medical device, and diagnostic opportunities. Hatteras has approximately $450 million under management in five venture capital funds. The firm is led by a seasoned team of entrepreneurs and operators and has a long and successful track record of seed and early stage investing and company formation. To learn more about Hatteras Venture Partners, please visit

StrideBio Contact
Richard E. T. Smith, PhD
[email protected]